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A best evidence topic was written according to a structured protocol. The question addressed was
whether there is a survival beneﬁt from life-long follow-up after treatment for thyroid cancer. A total of
137 papers were identiﬁed using the reported searches of which 7 represented the best evidence to
answer the clinical question. The authors, date, journal, study type, population, main outcome measures
and results are tabulated. The existing guidelines for follow-up in thyroid cancer recommend life-long
follow-up as recurrence may present after 5 years. However, the strategy of life-long follow-up for
everyone (as advised by the British, European and American Thyroid Association guidelines) is not
evidence-based. The issue is that some of the recurrences may present after 5 years and low volume
recurrence may be more effectively treated. However, as in many other malignancies, there is no study
that reliably shows a survival beneﬁt conferred from life-long follow-up, especially in stage 1 disease.
Moreover, the risk of recurrence only parallels the risk of disease-speciﬁc mortality in the older thyroid
cancer patient group (>45 years at diagnosis). The evidence from the present review supports a risk
stratiﬁed approach to follow-up for thyroid cancer since low-risk thyroid cancer is associated with low
recurrence rates and mortality compared to the other groups. For young patients (<45 years at diagnosis)
with stage 1 disease, there is no proven survival beneﬁt from life-long follow-up following primary
treatment. These patients could be safely discharged to primary care after 5 years for follow-up with
yearly thyroglobulin measurements.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a structured
protocol. This is fully described in a previous publication in the
International Journal of Surgery.1
2. Clinical scenario
A total thyroidectomy has been performed on a 31-year-old
woman with a 7 mm Thy 4 nodule. Histopathological assessment
reveals this to be a unifocal, well-differentiated papillary thyroid
carcinoma and demonstrates that the tumour is entirely conﬁned
to the thyroid gland and has been completely excised. There is noMedicine, London, UK on 3rd
Tanner Prize of the Section of
ry and Surgical Technology,
n W2 1NY, United Kingdom.
charakis).
ciates Ltd. Published by Elsevier Ltevidence of vascular invasion, extrathyroidal extension or lymph
node involvement. She is now 5 years post-treatment and all her
tests (thyroglobulin and neck ultrasound) have shown no evidence
of recurrence. She is asking you whether she can be given the “all
clear” and be discharged from follow-up. You resolve to assess the
literature yourself.
3. Three-part question
In young (<45 years at diagnosis) patients with low risk of
recurrence and very low or low risk of death from thyroid cancer
who have demonstrated an excellent response to thyroidectomy is
there survival beneﬁt from life-long follow-up?
4. Search strategy
Medline search 1948e2012 using the PubMed interface for the
terms:
(follow [All Fields] AND up[All Fields]) AND (“thyroid neo-
plasms”[MeSHTerms] OR (“thyroid”[All Fields] AND “neoplasms”[Alld. All rights reserved.
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REVIEWFields]) OR “thyroid neoplasms”[All Fields] OR (“thyroid”[All Fields]
AND “cancer”[All Fields]) OR “thyroid cancer”[All Fields]) AND
((“life”[MeSH Terms] OR “life”[All Fields]) AND long [All Fields]) AND
(“mortality”[Subheading] OR “mortality”[All Fields] OR “survival”[All
Fields] OR “survival”[MeSH Terms]).
In addition, the reference lists of the relevant papers were
searched. The search was current as of 27th November 2012.
5. Search outcome
137 papers were found using the reported search. Two authors
(G.G. and O.J.) independently assessed the titles and abstracts of the
identiﬁed articles to determine potential relevance. Any disagree-
ment was resolved by discussion or with the opinion of the senior
author (E.Z.). After reviewing the abstracts, 51 papers were selected
to be fully appraised in view of relevance and methods used. From
these, 21 were irrelevant, 18 were review articles, 2 were not in
English, 2 were studies involving paediatric patients and 1 assessed
patients with other histological types of thyroid cancer. Inclusion
criteria included studies of any size, prospective or retrospective in
design that assessed survival outcomes for patients with differen-
tiated thyroid cancer. All patients included had to be adults and had
to have received appropriate treatment. Exclusion criteria included
studies including paediatric patients or patients with other histo-
logical types of thyroid cancer. Review articles and studies where
the patients had not been sub-grouped according to their histology
or disease stage to allow risk-stratiﬁcation were also excluded.
Based on design, number of patients and origin (high volume/
specialised centres and national registries) 7 papers were chosen as
representing the best evidence to answer the clinical question.
6. Results
The results of the seven papers (one prospective, six retro-
spective studies) are summarised in Table 1.
7. Discussion
Differentiated thyroid cancer (DTC) in the young (<45 years)
which has been optimally treated usually confers a favourable
prognosis. This is based on the combination of the biological
behaviour of the majority of these tumours (low tumourigenicity)2
and effective initial therapy (total thyroidectomy [TT] with or
without radioactive iodine [RAI]).3
The existing guidelines for follow-up are based on low-level
evidence, namely retrospective studies derived from analyses of
patients treated in the distant past and collected over several
decades.4 Prospective clinical trials with meaningful follow-up
periods would be nearly impossible to perform due to the very
long follow-up periods required.2
The current international guidelines (from the British, European
and American Thyroid Associations) advocate life-long follow-up
for DTC. However, this strategy of life-long follow-up for everyone
is not evidence-based as there is no study to demonstrate a survival
beneﬁt in patients for stage 1 disease (absence of distant metas-
tases, age <45 years at diagnosis or <2 cm tumour size in older
patients) since survival in optimally treated patients is very good.2,3
Moreover, it is important to appreciate that the risk of recurrence of
DTC does not parallel the risk of disease-speciﬁc mortality in young
patients (<45 years at diagnosis).5
In their study, Brassard et al.6 prospectively followed-up 715
DTC patients with no anti-thyroglobulin (Tg) antibodies who had
complete resection of neoplastic foci via TT (and level VI neck
dissection [ND] in 94% of cases) at the primary surgery followed by
RAI post-operatively with no focus of uptake detected outside thethyroid bed on the total body scan (TBS) 3e5 days following RAI.
These patients represent the majority of cases in a typical thyroid
cancer practice. All patients were then treated with levothyroxine
(LT4). Only 32 (4.5%) developed a detectable recurrence. Of these,
53% (17) occurred in the ﬁrst 2 years and 91% (29) in the ﬁrst 5
years. Recurrence rates increased with progressively increasing
T and N status. Tg was found to discriminate well between those
patients who experienced a detectable recurrence and those who
remained free of disease. The cut-off values identiﬁed were 0.27 ng/
ml and 1.4 ng/ml for Tg1 (on LT4) and Tg2 (on TSH stimulation)
respectively. In addition, Tg levels were found to correlate well with
disease burden. Weaknesses of the study include the limited
number of events (32 recurrences), short median follow-up (6.2
years) and the fact that different local procedures for follow-up
were employed as this represents a multicentre study.
Hay et al.7 in the largest study of patients with papillary thyroid
microcarcinoma (PTMC) (cancers under 1 cm in diameter) to date
(n ¼ 900) encompassing over 15,000 years of follow-up, showed
that patients with PTMC have an excellent prognosis. More
speciﬁcally, in the subgroup of patients presenting with intra-
thyroidal, node-negative disease (n ¼ 627), provided complete
tumour resection was achieved, the recurrence rate was a mere
0.8%. In addition, they showed that cervical recurrence was not
associated with increased mortality. All patients that succumbed to
their disease (only 0.3% of total) initially presented with either
extensive regional nodal or distant metastases. The authors
conclude that PTMC represents a life-threat in only a tiny minority
of patients, and those few patients can be identiﬁed at the time of
diagnosis. The main limitation of this study is its retrospective
nature though the very large number of patients (n ¼ 900) and
mean follow-up period of 17.2 years (range 0.1e54 years)
compensate for this to provide very valuable and statistically
signiﬁcant information.
Lundgren et al.8 conducted a retrospective review of 5554 DTC
patients with a mean follow-up of 17 and 15 years for papillary
(PTC) and follicular thyroid carcinoma (FTC) respectively. Despite
its retrospective nature, this study possesses several strengths as it
comprises of a large population-based cohort with a long follow-up
period and detailed information on histopathology (available
through the Swedish Cancer Registry). The authors found prognosis
to be related to histology (PTC better than FTC though this could be
due to the confounding of age), age at diagnosis (better prognosis
for patients <40 years at diagnosis), gender (women experienced
superior survival to men) and calendar year of diagnosis (better
prognosis for patients diagnosed later in the study suggesting the
presence of lead time bias and improved surgery). The majority of
deaths were shown to occur during the years immediately after
diagnosis. This further reinforces the lack of survival beneﬁt from
long-term follow-up for DTC as the total excess mortality was
shown to be relatively low during the period 7e20 years after
diagnosis. Limitations included the lack of information on tumour
stage at diagnosis and misclassiﬁcation of certain cases of FTC.
Hundahl et al.4 in a retrospective analysis of 53,856 thyroid
carcinoma patients from a national US database (NCDB) repre-
senting the largest existing series in the international literature,
showed that the 5-year relative survivals for stage 1 PTC and stage 1
FTC were 100% and 99% respectively. They also found age to be an
important prognostic factor. Both of these ﬁndings are in agree-
ment with the other (smaller) studies in the literature. Limitations
of this study include its retrospective nature and the fact that the
authors were unable to derive ﬁgures for longer stage-stratiﬁed
relative survival for PTC and FTC due to a change in AJCC coding
that took place in 1988 when its 3rd edition was published.
Shaha et al.9 in a retrospective analysis of data from 1038 DTC
patients, 465 of which were stratiﬁed as low-risk (<45 years at
Table 1
Best evidence papers.
Author, date
and country
Patient group Study type and
level of evidence
Outcomes Key results Comments
Brassard et al.
2011,6 France
715 DTC patients (papillary and follicular)
with no anti-Tg antibodies who had
complete resection of neoplastic foci via
TT (and level VI ND in 94% of cases)
followed by RAI post-operatively and
had no focus of uptake detected outside
the thyroid bed on the 123I-TBS 3e5 days
following RAI. All patients were then
treated with LT4
Median follow-up was 6.2 years
(range 9 monthse9.6 years)
Mean age: 47 years (range 13e80 years),
77% women
Histology: 86.4% PTC and 13.6% FTC
Level IIb prospective
cohort study
Predictive values of Tg levels
on the long-term risk of
recurrence calculated by
measuring Tg on LT4 therapy
at 3e4 months after RAI (Tg1)
and at 9e12 months after
stimulation by either LT4
withdrawal or rhTSH (Tg2)
and comparing Tg1 and Tg2
levels with the outcome in
terms of recurrence.
32/715 (4.5%) patients had a recurrence
identiﬁed on follow-up
The recurrence rate reached 4.2% at
5 years (95%CI ¼ 2.9e6.1)
Of those patients that did have a
recurrence (n ¼ 32), 17/32 (53%)
occurred in the ﬁrst 2 years and 29/32
(91%) occurred in the ﬁrst 5 years of
follow-up
Of those patients that did have a recurrence
(n ¼ 32), only 7 occurred in the 424 pT1-T2,
N0 patients (1.7%). This relative percentage
of recurrence rate increased with
progressively worsening T and N status
The negative predictive values of both
Tg1 (when <0.27 ng/ml) and Tg2
(when <1.4 ng/ml) were found to be 99%
TSH stimulation did not increase the
negative predictive value of Tg determination
on the risk of recurrence, which was 99% in
both conditions, thus, TSH-stimulated Tg
determination (Tg2) may not be necessary
if Tg1<0.27 ng/ml
The patients included in this study represent
the great majority of cases in clinical practice.
This is because all 715 patients included had
no focus of uptake detected outside the
thyroid bed on the 123I-TBS (3e5 days
following RAI post-TT)
The cutoff values of 0.27 ng/ml and 1.4 ng/ml
for Tg1 (on LT4) and Tg2 (on TSH stimulation),
respectively, discriminated well between
patients who experienced a recurrence and
those who remained free of disease
In addition to its excellent (99%) negative
predictive value for disease recurrence, in
those patients that do suffer recurrence,
Tg levels correlate well with disease burden
TSH stimulation improves the positive
predictive value of serum Tg determination
(Tg2) only in patients with a Tg level on
LT4 (Tg1) >0.24 ng/ml, and its use may
be restricted to these patients (also
improving cost-effectiveness of follow-up)
Limitations: limited number of events
(32 recurrences), median follow-up of
only 6.2 years, multicentre study so
different local procedures for follow-up
Hay et al.
2008,7 USA
Retrospective analysis of 900 cases of
PTMC from a computerised database
(Mayo Clinic Rochester Thyroid Cancer
Database) held between 1945 and 2004
Mean age: 46 years (range 6e89),
70% women
Histology: all PTMC
Surgical pathological characteristics:
median tumour size 7 mm
(range 1e10 mm), 98% of the tumours
had a histologic grade I, 23% of cases
multifocal PTMC
Extent of tumour at diagnosis: 30%
had cervical lymph node metastases
at presentation and 0.3% had distant
metastases, 98% of patients classiﬁed
as “low-risk”
Follow-up: mean follow-up was
17.2 years (range 0.1e54 years)
Level III retrospective
cohort study
Better characterisation of
the PTMC patients
presenting to the Mayo
Clinic (Rochester, MN)
Provision of data on
outcome after surgical
and medical therapy
At the conclusion of the study:
 70% of patients were living with no
evidence of thyroid cancer
 0.3% had died of thyroid cancer
 29% had died of other causes
 0.1% patients were alive with evidence
of pulmonary metastases
Cause-speciﬁc mortality rates:
 10 years: 0.1%
 20 years: 0.1%
 30 years: 0.7%
 40 years: 0.7%
No female with localised cervical
disease died of PTMC
No male patient died of PTMC in the
ﬁrst 25 post-operative years
None of the 892 patients with
initial complete tumour resection
developed distant spread during
the ﬁrst 20 post-operative years
Primary message: Patients with PTMC have
an excellent prognosis
All cause mortality from PTMC mirrors the
anticipated mortality in a Midwestern
population of similar age and gender
Cause-speciﬁc mortality from PTMC is
rare (0.3%)
Among the 627 patients with intrathyroidal,
node-negative disease at diagnosis, the
recurrence rate was a mere 0.8%
Nevertheless, cervical recurrence was not
associated with an increased mortality
Of the 0.3% of patients that succumbed
to their thyroid cancer, they all presented
with either extensive regional nodal or
distant metastases
Conclusion: PTMC represents a life-threat
in only a tiny minority of patients, and
those few patients can be identiﬁed at
the time of diagnosis
Strengths: This study, encompassing
over 15,000 patient-years of follow-up
is the largest study of its type to date
Limitations: Retrospective study
Lundgren et al.
2003,8 Sweden
Retrospective review of 7906 patients
diagnosed with thyroid cancer between
1958 and 1987 in Sweden (as recorded
by Swedish Cancer Registry)
Of these, 5554 patients who had DTC
were selected (papillary and
Level III retrospective
cohort study
Prognosis of patients
diagnosed with DTC in
relation to:
- Histology
- Age at diagnosis
- Gender
The majority of deaths occur during
the years immediately after diagnosis
- Papillary thyroid cancer carries a
more favourable diagnosis than
follicular (could be due to confounding
effect of age)
Total excess mortality is relatively
low 7e20 years after diagnosis
Study data suggest that there may
be a subgroup of female DTC patients
diagnosed during the fertile par t of
life with a superior prognosis
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follicular - mixed tumours included
in papillary group)
Mean age: 50 years for PTC and 56
years for FTC, 75% women
Histology: 65% PTC and 35% FTC
Follow-up: mean for papillary group
was 17 years and mean for follicular
group was 15 years
- Calendar year of
diagnosis
- Survival declined with increased age,
better prognosis for patients <40
- Women experience a more superior
survival than men
- Better prognosis for patients
diagnosed later in study (lead
time bias vs. screening leading
to earlier diagnosis)
Strengths: Large population-based
cohort, long follow-up, detailed
information on histopathology
Limitations: lack on information on
the stage of the tumour at diagnosis,
misclassiﬁcation of certain cases of
follicular thyroid carcinoma (about
10% of the samples originally
labelled as follicular thyroid
carcinoma were re-classiﬁed as
either benign or papillary thyroid
carcinoma)
Hundahl et al.
1998,4 USA
Retrospective analysis of National
Cancer Data Base (NCDB) capturing
nearly 60% of incident cancers in the
US (1985e1995), n ¼ 53,856
No other demographic details for
patients provided
Histology: 42,686 (79%) PTC, 6764
(13%) FTC, 4406 (8%) other
Follow-up: restricted to 5 years for
determination of stage-speciﬁc
survival due to change in AJCC
staging coding when its 3rd
edition was published (1988)
Level III retrospective
cohort study
For each histologic type
of thyroid carcinoma:
- Overall 10-year
relative survival
- AJCC stage-stratiﬁed
5-year relative survival
AJCC stage 1 PTC: 100% overall 5-year
relative survival
AJCC stage 1 FTC: 99% overall 5-year
relative survival
Age at diagnosis appears to inﬂuence
the prognosis
Primary message: Patients with AJCC stage
1 DTC have an excellent prognosis
Strengths: cohort represents the largest
existing series (n ¼ 53,856), accurate
database on a national scale (USA)
Limitations: retrospective design, change
in AJCC staging meant that only data
coded after publication of the 3rd edition
of the AJCC manual (1988) could be
analysed resulting in only 5-year
stage-stratiﬁed results despite
10 years of data
Shaha et al.
1997,9 USA
Retrospective review of 1038
patients with DTC
465 patients were in the low-risk group
(age <45 years, tumour <4 cm in size,
low-grade histology, absence of distant
metastases, absence of extrathyroidal
extension)
Of the low risk group (n ¼ 465):
Histology: 403 (87%) PTC and
62 (13%) FTC
Gender: 120 (26%) male and
345 (74%) female
Mean age: 31 years
278 (60%) presented with clinically
apparent LN metastases
Median follow-up: 20 years
Level III retrospective
cohort study
10- and 20-year survival
Local, regional and
distant recurrence
rates based on extent
of surgery
Outcome comparison
of different surgical
approaches (partial vs. TT)
For the low risk group (n ¼ 465),
10- and 20-year survival was 99%
The local, regional and distant
recurrence rates were 5, 9 and
2% in this series
There was no statistical difference
between PTC and FTC for local and
regional recurrence
The incidence of distant metastasis
was 2% for PTC and 6% for FTC (p ¼ 0.03)
Extrathyroidal extension appears
to be a major prognostic factor,
especially for local recurrence in
level VI
There was no survival difference
between various histologies or
nodal status
Patients with low-risk DTC have excellent
long-term survival
Strengths: large cohort (n ¼ 1038), long
follow-up period (median 20 years)
Limitations: retrospective analysis,
variability in treatment (partial vs. TT),
failure to retrieve all tissue blocks for
histological review
Gilliland et al.
1997,10 USA
Retrospective analysis of data collected
by the Surveillance, Epidemiology and
End Results (SEER) programme of the
National Cancer Institute (1973e1991),
n ¼ 15,698
Histology: 74% PTC, 18% FTC, 8% other
Median follow-up: 82 months
Level III retrospective
cohort study
Investigation of prognostic
factors for each of the major
histologic types of thyroid
carcinoma
Assess the effect of these
factors as predictors of
survival
PTC 10-year relative survival: 98%
(99% for patients <40 years at diagnosis)
FTC 10-year relative survival: 92%
(98% for patients <40 years at diagnosis)
Stage at diagnosis and differentiation
status were strong independent
prognostic factors for each histologic
type
Risk of death was 50% greater in
males than females for both PTC
and FTC
Primary message: Patients with PTC and
FTC have an excellent prognosis esp. if
young (<45 years at diagnosis)
Strengths: very large cohort (n ¼ 15,698),
large and diverse population, case
ascertainment and follow-up through
the population-based SEER cancer
registries eliminated selection and
referral biases
Limitations: retrospective analysis,
histologic classiﬁcation of tumours
based on review of pathology reports
thus no standardised pathology review,
treatment was not controlled and may
have inﬂuenced survival
Lerch et al.
1997,11 Germany
Retrospective analysis of mortality and
survival rate in 500 patients (380 women
Level III retrospective
cohort study
In all, 29 (5.8%) of 500 patients
died, 19 (3.8%) of thyroid cancer
Primary message: Patients with low-risk
(pT1-3NxM0) DTC have an excellent
(continued on next page)
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REVIEWdiagnosis, tumour <4 cm in size, low-grade histology, absence of
distant metastases and absence of extrathyroidal extension)
showed that low-risk DTC is clearly a distinct entity with an
excellent survival. In this select group with a median follow-up of
20 years, the 10- and 20-year survival was 99%. Moreover, the
incidence of local, regional and distant metastasis was shown to be
very small and not mirroring disease-speciﬁc mortality. Despite its
retrospective nature, this study provides very valuable, statistically
signiﬁcant results due to the large number of patients included and
their very long follow-up period.
Gilliland et al.10 in a retrospective analysis of data from 15,698
patients collected by the Surveillance, Epidemiology and End
Results (SEER) programme from the National Cancer Institute
(1973e1991) with a median follow-up of 82 months, found that
both PTC and FTC bear an excellent prognosis (99% and 98% 10-year
relative survivals respectively). Age and stage at diagnosis along
with differentiation status were shown to be the most important
prognostic factors. Males were found to have a 50% higher risk of
death than females. Despite the limitations of this study, mainly
related to its retrospective nature, statistically signiﬁcant and
clinically valuable results can be derived as the patient cohort was
very large and the follow-up relatively long. Finally, selection and
referral biases were minimised through the presence of the
population-based SEER cancer registries.
Lerch et al.11 in a retrospective study of 500 DTC patients (all
TNM stages) with a median follow-up of 5.8 years (range 0e23
years), risk stratiﬁed the patients into low-risk (pT1-3N0M0) and
high-risk (pT4 and/or M1) groups and showed that, in contrast to
the high-risk group, low-risk patients had a signiﬁcantly higher
survival rate (97%, p < 0.0001) with no patient in that group dying
of thyroid cancer (contrary to the high-risk group). Moreover, on
univariate analysis, they found that age was an important prog-
nostic factor for DTC as in the overall patient cohort the survival
rate of patients older than 40 years was 90% compared to 96% in
younger patients. Despite its limitations (retrospective study with
short follow-up), valuable conclusions can be derived from this
study as it contained a large number of patients that were
uniformly treated. What is of particular value is the fact that the
authors sub-grouped the patients in high- and low-risk groups
comparing outcomes in the two and illustrating the importance of
risk stratiﬁcation in the follow-up of DTC.12,13
Limitations of this study include the fact that the majority of the
studies reviewed were retrospective. This however, as discussed
above, is a result of the paucity of prospective studies in the liter-
ature and does not reﬂect the search strategy employed. As stated
earlier, adequately powered prospective clinical trials would be
nearly impossible to conduct due to the very long follow-up periods
required.2 The one prospective study that does exist on the subject
was included.6 Moreover, only 7 studies were selected for an
in-depth review and no attempt was made to statistically aggregate
the data. However, this is the aim of a best evidence topic; to
answer a focused clinical question rather than perform a full
exhaustive systematic review.1 Moreover, statistical analysis would
not have been possible due to the signiﬁcant heterogeneity of the
data given the differences in inter-study follow-up periods and
variability of patient groups. All the above studies are complicated
by the fact that frequently PTMC, a disease that as demonstrated by
the large Mayo clinic series by Hay et al.7 has no mortality has been
groupedwith stage 1 thyroid cancers of greater than 1 cm diameter.
This has to be borne in mind when considering the published data.
Strengths of this study include the fact that it answers a very
creditable clinical question that has long been debated. The question
is timely as we think of the increasing costs of healthcare and ﬁnite
resources available. The methodology is robust and particularly
appropriate to answer such a focused question in surgery. This was
G. Garas et al. / International Journal of Surgery 11 (2013) 116e121 121
REVIEWachieved through thehigh sensitivityof the search strategyused that
ensured retrieval of all relevant papers. This study provides a prac-
tical answer of immediate use to surgeons in their daily practice.1
8. Clinical bottom line
The strategy of life-long follow-up for everyone with thyroid
cancer (as advised by the British, European and American Thyroid
Association guidelines) is like so many other cancers not evidence-
based. It is based on the reasonable assumption that an early
diagnosis of recurrence makes treatment with surgery or RAI more
effective. It appears clear despite the weakness and lack of homo-
geneity of the published data that the follow-up for thyroid cancer
should be individualised both on clinical and economic grounds.
Low-risk DTC constitutes a distinct entity with excellent survival
that can probably only marginally be improved by intensive follow-
up. The same is not true for the less common higher risk patients.
Some thyroid cancer recurrence may present after 5 years and has
to be factored into the follow-up methodology and subsequent
strategy. However, there is no incontrovertible evidence that shows
a survival beneﬁt being conferred from life-long follow-up in stage
1 disease. Moreover, the risk of recurrence only parallels the risk of
disease-speciﬁc mortality in the older thyroid cancer patient group
(>45 years at diagnosis).
For young patients (<45 years at diagnosis) with stage 1 DTC,
there is no proven survival beneﬁt conferred by life-long follow-up
following optimal initial treatment. These patients could probably
be safely discharged to primary care after 5 years for follow-upwith
yearly thyroglobulin measurements. Clear instructions should be
provided in the discharge letter to the primary care physician as to
when a re-referral to the multidisciplinary thyroid cancer team is
mandated.
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